Premium
Glioblastoma chemotherapy adjunct via potent serotonin receptor‐7 inhibition using currently marketed high‐affinity antipsychotic medicines
Author(s) -
Kast RE
Publication year - 2010
Publication title -
british journal of pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.432
H-Index - 211
eISSN - 1476-5381
pISSN - 0007-1188
DOI - 10.1111/j.1476-5381.2010.00923.x
Subject(s) - pharmacology , medicine , serotonin , 5 ht2a receptor , serotonin antagonists , antipsychotic , receptor , 5 ht receptor , cancer research , biology , schizophrenia (object oriented programming) , psychiatry
Glioblastoma treatment as now constituted offers increased survival measured in months over untreated patients. Because glioblastomas are active in synthesizing a bewildering variety of growth factors, a systematic approach to inhibiting these is being undertaken as treatment adjunct. The serotonin 7 receptor is commonly overexpressed in glioblastoma. Research documentation showing agonists at serotonin receptor 7 cause increased extracellular regulated kinase 1/2 activation, increased interleukin‐6 synthesis, increased signal transducer and activator of transcription‐3 activation, increased resistance to apoptosis and other growth enhancing changes in glioblastoma is reviewed in this paper. Because three drugs in wide use to treat thought disorders – paliperidone, pimozide and risperidone – are also potent and well‐tolerated inhibitors at serotonin receptor 7, these drugs should be studied for growth factor deprivation in an adjunctive role in glioblastoma treatment.